Exchange: NASDAQ·Updated 11:39 AM EDT
News
all
press releases
TG Therapeutics (TGTX) Up 15.1% Since Last Earnings Report: Can It Continue?
TG Therapeutics (TGTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
More News
TGTX Stock Pares Opening Losses After Analyst Dismisses Competition From Novartis
TGTX shares opened lower on Tuesday after Novartis said its drug remibrutinib improved multiple sclerosis in late-stage trials.
Stocktwits
TGTX Stock On Track For Best Day In 3.5 Months Amid Fresh Buyout Rumors
The mergers and acquisitions-focused blog Betaville published an alert on Friday signaling fresh interest from an unnamed suitor for TG Therapeutics, Seeking Alpha reported.
Stocktwits
TG Therapeutics (TGTX) Q2 2026 Earnings Call Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets
Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for high unmet need diseases, today reported financial results for the second quarter ended June 30, 2026, and provided a...
Business Wire
TGTX Q2 Earnings Lag, Sales Rise Y/Y, 2026 View Raised, Stock Down
TG Therapeutics misses Q2 earnings estimates, but surging Briumvi demand lifts revenues y/y and prompts higher 2026 revenue guidance. Stock falls.
Zacks
Here's What Key Metrics Tell Us About TG Therapeutics (TGTX) Q2 Earnings
The headline numbers for TG Therapeutics (TGTX) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Zacks
TG Therapeutics CEO Says Briumvi Is On Track To Become A $1B US Drug – Retail Shrugs Off EPS Miss
The biotech firm increased its 2026 total global revenue target to around $950 million, up from $925 million previously.
Stocktwits
TG Therapeutics (TGTX) Misses Q2 Earnings Estimates
TG Therapeutics (TGTX) delivered earnings and revenue surprises of -87.81% and +4.08%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Earnings Preview: Amgen (AMGN) Q2 Earnings Expected to Decline
Amgen (AMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks

Advertisement|Remove ads.